New cancer pill AN4005 enters first human tests

NCT ID NCT04999384

Recruiting now Disease control Sponsor: Adlai Nortye Biopharma Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new experimental drug called AN4005 in about 31 people with advanced solid tumors or lymphoma that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Participants take the drug by mouth twice a day at different dose levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AN4005 (an experimental drug taken as a pill)
What this could lead to: If this trial succeeds, it could point toward a new treatment option for people with advanced solid tumors or lymphoma who have run out of standard therapies.
What could go wrong: This is a very early, first-in-human study with only 31 participants. The drug may not be safe or effective at higher doses, and side effects are unknown. Many early-stage cancer drugs never advance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lymphoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED LYMPHOMA ADVANCED SOLID TUMOR

Contacts and locations

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, 100142, China
Hackensack University Medical Center
RECRUITING

Hackensack, New Jersey, 07601, United States
Harbin Medical University Cancer Hospital
RECRUITING

Harbin, Heilongjiang, 150081, China
Montefiore Einstein Cancer Center
RECRUITING

The Bronx, New York, 10461, United States
Next Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
Prisma Health Institute for Translational Oncology Research
RECRUITING

Greenville, South Carolina, 29605, United States
Union Hospital Tongji Medical College Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, 430000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.